VerbatimParliament, as it happens

Puberty Suppressing Hormones: Gender Dysphoria

Asked by Rupert LoweRestore BritainDepartment of Health and Social CareTabled Answered 17 December 2025UIN 94872

The question

To ask the Secretary of State for Health and Social Care, what evidence NICE has identified as the basis for its clinical assessment of puberty blockers for gender dysphoria; and whether NICE has undertaken (a) scoping and (b) evaluation exercises since 2015.

Answered by Dr Zubir Ahmed

The National Institute for Health and Care Excellence (NICE) has not developed guidance on, or made a clinical assessment of, puberty blockers for gender dysphoria. In 2020, NICE developed two evidence summaries:

  • Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria; and
  • Gender-affirming hormones for children and adolescents with gender dysphoria.

These summaries were commissioned by NHS England and developed by NICE to an NHS England process. They helped inform the Cass review.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim